Immix Biopharma, Inc. (IMMX)
IMMX Stock Price Chart
Explore Immix Biopharma, Inc. interactive price chart. Choose custom timeframes to analyze IMMX price movements and trends.
IMMX Company Profile
Discover essential business fundamentals and corporate details for Immix Biopharma, Inc. (IMMX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
16 Dec 2021
Employees
18.00
Website
https://www.immixbio.comCEO
Ilya Rachman
Description
Immix Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to creating a range of tissue-specific therapies. Operating in both the United States and Australia, their primary focus areas are oncology (cancer) and inflammatory diseases. Their product pipeline includes IMX-110, which is currently undergoing Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and various solid tumors. They are also developing IMX-111, a targeted biologic agent for colorectal cancers, and IMX-120, another tissue-specific biologic designed to address ulcerative colitis and severe Crohn's disease. In a strategic move, the company has forged a clinical collaboration and supply agreement with BeiGene Ltd. This partnership aims to conduct a Phase 1b combination clinical trial, evaluating IMX-110 in conjunction with BeiGene's anti-PD-1 drug, Tislelizumab, for solid tumor indications. Founded in 2012, Immix Biopharma maintains its headquarters in Los Angeles, California.
IMMX Financial Timeline
Browse a chronological timeline of Immix Biopharma, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 14 Aug 2026
EPS estimate is -$0.17.
Earnings released on 7 May 2026
EPS came in at -$0.18 surpassing the estimated -$0.18 by +0.30%.
Earnings released on 25 Mar 2026
EPS came in at -$0.27 falling short of the estimated -$0.21 by -28.57%.
Earnings released on 7 Nov 2025
EPS came in at -$0.24 falling short of the estimated -$0.19 by -26.32%.
Earnings released on 8 Aug 2025
EPS came in at -$0.22 falling short of the estimated -$0.21 by -4.76%.
Earnings released on 8 May 2025
EPS came in at -$0.15 surpassing the estimated -$0.23 by +34.78%.
Earnings released on 24 Mar 2025
EPS came in at -$0.16 surpassing the estimated -$0.25 by +36.00%, while revenue for the quarter reached $96.29k .
Earnings released on 12 Nov 2024
EPS came in at -$0.24 falling short of the estimated -$0.16 by -50.00%.
Earnings released on 12 Aug 2024
EPS came in at -$0.15 surpassing the estimated -$0.21 by +28.57%.
Earnings released on 9 May 2024
EPS came in at -$0.22 surpassing the estimated -$0.23 by +4.35%.
Earnings released on 29 Mar 2024
EPS came in at -$0.24 falling short of the estimated -$0.23 by -4.35%, while revenue for the quarter reached $4.78k .
Earnings released on 9 Nov 2023
EPS came in at -$0.23 matching the estimated -$0.23.
Earnings released on 11 Aug 2023
EPS came in at -$0.24 falling short of the estimated -$0.17 by -41.18%.
Earnings released on 12 May 2023
EPS came in at -$0.18 falling short of the estimated -$0.14 by -28.57%.
Earnings released on 27 Mar 2023
EPS came in at -$0.27 falling short of the estimated -$0.22 by -22.73%, while revenue for the quarter reached -$89.52m .
Earnings released on 9 Nov 2022
EPS came in at -$0.11 .
Earnings released on 12 Aug 2022
EPS came in at -$0.11 .
Earnings released on 13 May 2022
EPS came in at -$0.10 .
Earnings released on 28 Mar 2022
EPS came in at -$3.00 .
Earnings released on 30 Sept 2021
EPS came in at -$0.06 .
IMMX Stock Performance
Access detailed IMMX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
